BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31719675)

  • 1. Longitudinal neovascular changes on optical coherence tomography angiography in proliferative diabetic retinopathy treated with panretinal photocoagulation alone versus with intravitreal conbercept plus panretinal photocoagulation: a pilot study.
    He F; Yu W
    Eye (Lond); 2020 Aug; 34(8):1413-1418. PubMed ID: 31719675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study).
    Figueira J; Fletcher E; Massin P; Silva R; Bandello F; Midena E; Varano M; Sivaprasad S; Eleftheriadis H; Menon G; Amaro M; Ayello Scheer S; Creuzot-Garcher C; Nascimento J; Alves D; Nunes S; Lobo C; Cunha-Vaz J;
    Ophthalmology; 2018 May; 125(5):691-700. PubMed ID: 29395119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Observation of retinal neovascularization using optical coherence tomography angiography after panretinal photocoagulation for proliferative diabetic retinopathy.
    Feng HE; Weihong YU; Dong F
    BMC Ophthalmol; 2021 Jun; 21(1):252. PubMed ID: 34098891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy.
    Filho JA; Messias A; Almeida FP; Ribeiro JA; Costa RA; Scott IU; Jorge R
    Acta Ophthalmol; 2011 Nov; 89(7):e567-72. PubMed ID: 21726427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study).
    Tonello M; Costa RA; Almeida FP; Barbosa JC; Scott IU; Jorge R
    Acta Ophthalmol; 2008 Jun; 86(4):385-9. PubMed ID: 17995982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Panretinal Photocoagulation Plus Intravitreal Bevacizumab Versus Panretinal Photocoagulation Alone for Proliferative Diabetic Retinopathy.
    Ali W; Abbasi KZ; Raza A
    J Coll Physicians Surg Pak; 2018 Dec; 28(12):923-927. PubMed ID: 30501828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of conbercept combined with panretinal photocoagulation in the treatment of proliferative diabetic retinopathy.
    He F; Yang J; Zhang X; Yu W
    Sci Rep; 2020 May; 10(1):8778. PubMed ID: 32472048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CHOROIDAL THICKNESS CHANGES IN PROLIFERATIVE DIABETIC RETINOPATHY TREATED WITH PANRETINAL PHOTOCOAGULATION VERSUS PANRETINAL PHOTOCOAGULATION WITH INTRAVITREAL BEVACIZUMAB.
    Roohipoor R; Sharifian E; Ghassemi F; Riazi-Esfahani M; Karkhaneh R; Fard MA; Zarei M; Modjtahedi BS; Moghimi S
    Retina; 2016 Oct; 36(10):1997-2005. PubMed ID: 27046456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy.
    Messias A; Ramos Filho JA; Messias K; Almeida FP; Costa RA; Scott IU; Gekeler F; Jorge R
    Doc Ophthalmol; 2012 Jun; 124(3):225-36. PubMed ID: 22457045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Panretinal photocoagulation after or prior to intravitreal conbercept injection for diabetic macular edema: a retrospective study.
    Zhang W; Zhao G; Fan W; Zhao T
    BMC Ophthalmol; 2021 Apr; 21(1):160. PubMed ID: 33789617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panretinal photocoagulation versus panretinal photocoagulation plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy.
    Zhou AY; Zhou CJ; Yao J; Quan YL; Ren BC; Wang JM
    Int J Ophthalmol; 2016; 9(12):1772-1778. PubMed ID: 28003978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topographical Response of Retinal Neovascularization to Aflibercept or Panretinal Photocoagulation in Proliferative Diabetic Retinopathy: Post Hoc Analysis of the CLARITY Randomized Clinical Trial.
    Halim S; Nugawela M; Chakravarthy U; Peto T; Madhusudhan S; Lenfestey P; Hamill B; Zheng Y; Parry D; Nicholson L; Greenwood J; Sivaprasad S
    JAMA Ophthalmol; 2021 May; 139(5):501-507. PubMed ID: 33704351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ETDRS panretinal photocoagulation combined with intravitreal ranibizumab versus PASCAL panretinal photocoagulation with intravitreal ranibizumab versus intravitreal ranibizumab alone for the treatment of proliferative diabetic retinopathy.
    Barroso RMP; Messias K; Garcia DM; Cardillo JA; Scott IU; Messias A; Jorge R
    Arq Bras Oftalmol; 2020; 83(6):526-534. PubMed ID: 33470281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinal function in eyes with proliferative diabetic retinopathy treated with intravitreal ranibizumab and multispot laser panretinal photocoagulation.
    Messias K; Barroso RM; Jorge R; Messias A
    Doc Ophthalmol; 2018 Oct; 137(2):121-129. PubMed ID: 30209775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison between the therapeutic effects of Conbercept combined with panretinal photocoagulation and panretinal photocoagulation monotherapy for high-risk proliferative diabetic retinopathy.
    Sun Y; Qi H
    Front Endocrinol (Lausanne); 2022; 13():1038757. PubMed ID: 36714571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequence effect in the treatment of proliferative diabetic retinopathy with intravitreal ranibizumab and panretinal photocoagulation.
    Cao G; Xu X; Wang C; Zhang S
    Eur J Ophthalmol; 2020 Jan; 30(1):34-39. PubMed ID: 30539668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Real-World Outcomes of Corneal Changes in Proliferative Diabetic Retinopathy: Panretinal Photocoagulation vs. Intravitreal Conbercept.
    Li Z; Zhou L; Huang C; Lu T; Liang J; Cong Q; Lan Y; Jin C
    Photodiagnosis Photodyn Ther; 2023 Dec; 44():103765. PubMed ID: 37625766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial.
    Preti RC; Ramirez LM; Monteiro ML; Carra MK; Pelayes DE; Takahashi WY
    Br J Ophthalmol; 2013 Jul; 97(7):885-9. PubMed ID: 23686001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Panretinal Photocoagulation Plus Intravitreal Anti-VEGF Treatment Against PRP Alone for Diabetic Retinopathy: A Systematic Review With Meta-Analysis.
    Zhang W; Geng J; Sang A
    Front Endocrinol (Lausanne); 2022; 13():807687. PubMed ID: 35422768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proliferative diabetic retinopathy treated with intravitreal ranibizumab and photocoagulation directed at ischemic retinal areas-A randomized study.
    Toscano L; Messias A; Messias K; de Cenço Lopes R; Ribeiro JAS; Scott IU; Jorge R
    Doc Ophthalmol; 2021 Dec; 143(3):313-322. PubMed ID: 34347216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.